Researchers Discover Method to Reduce Extreme Side Effects of Kidney Disease Drug
Tolvaptan is recognised as the only approved medication to slow the growth of cysts in patients with polycystic kidney disease (PKD). However, this drug carries extremely distressing side effects for patients, namely excessive urine production reaching six to seven litres per day. As a result, patients are forced to wake up multiple times during the night to use the bathroom.
For some patients, this burden is so difficult to endure that they choose to stop taking the medication. Now, an accidental discovery involving an old drug has the potential to change this reality.
The discovery began in the laboratory of Dr. Fouad Chebib, a nephrologist at the Mayo Clinic. His team was researching kidney cells to observe the progression of polycystic kidney disease, the most common hereditary disease that destroys healthy kidney tissue and triggers kidney failure.
At the time, researchers were testing the compound probenecid, a drug from the 1940s originally used to maintain penicillin antibiotic levels in the body during wartime. Initially, they suspected that probenecid would exacerbate cyst growth. However, the results showed the exact opposite.
“We thought this drug would worsen the disease process. Instead, it produced the opposite result,” said Chebib.
For decades, the scientific world believed that the body retains water primarily through a single hormone, vasopressin. Tolvaptan works by blocking this vasopressin signal so that cysts grow more slowly, but the impact causes the body to expel massive amounts of fluid.
Through this study, Chebib’s team discovered a second, previously hidden pathway. The molecule involved in this alternative pathway is urate, a substance that typically accumulates in the joints of gout sufferers. Within kidney cells, urate acts as an independent signal that instructs water channels in the cell walls to move to the surface, allowing the kidneys to retain more water and produce more concentrated urine without the help of vasorbassin.
Armed with this new understanding, the research team paired probenecid with tolvaptan in animal testing, and subsequently proceeded with a small group of patients. The results showed that this combination successfully reduced urine volume by one-third without reducing the effectiveness of tolvaptan in inhibiting cysts.
Patients who previously had to wake up multiple times every night are now reported to wake up only about once, and feel much better physically on a daily basis. This step was designed purely to alleviate the burden of patient treatment, not to replace the existing medication.
“The goal is to maintain the therapeutic benefits of tolvaptan while reducing its burden,” explained Chebib.
Although probenecid itself is unlikely to be used on a mass scale because it affects many other organs and its supply is becoming scarce, the discovery of this urate pathway opens new targets for future drug developers. This research has been officially published in the Journal of Clinical Investigation.
Source: jawawa.id (https://jawawa.id/newsitem/researchers-discover-method-to-reduce-extreme-side-effects-of-kidney-disease-drug-1782370328)
Originally published by Media Indonesia (https://mediaindonesia.com/humaniora/904122/peneliti-temukan-cara-redakan-efek-samping-ekstrem-obat-penyakit-ginjal), translated from Indonesian